{
    "clinical_study": {
        "@rank": "28464", 
        "arm_group": {
            "arm_group_label": "Intravitreal Lucentis 0.5mg", 
            "arm_group_type": "Other", 
            "description": "One arm"
        }, 
        "brief_summary": {
            "textblock": "In retinal vein occlusion, predictive factors for visual outcome after ranibizumab treatment\n      have not been evaluated comprehensively. Therefore, we have planned to analyze predictors\n      for visual outcome from a viewpoint of electrophysiology and biomarkers besides\n      morphological features by SD-OCT."
        }, 
        "brief_title": "Ranibizumab Treatment for Retinal Vein Occlusion", 
        "condition": "Macular Edema Due to BRVO/CRVO", 
        "condition_browse": {
            "mesh_term": [
                "Macular Edema", 
                "Retinal Vein Occlusion"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Signed informed consent form\n\n          -  Male or female of aged 18 years or older\n\n          -  Macula edema secondary to BRVO/CRVO\n\n          -  Decrease of VA due to macular edema\n\n        Exclusion Criteria:\n\n          -  Prior episode of RVO\n\n          -  Previous treatment with anti-VEGF drugs or corticosteroid or grid laser\n             photocoagulation (study eye)\n\n          -  Ocular disorders in the study eye that may confound interpretation of study results\n\n          -  History of vitrectomy surgery, submacular surgery, or other surgical intervention for\n             RVO\n\n          -  The pregnant or lactating woman"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 20, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01968616", 
            "org_study_id": "KY-RV-R"
        }, 
        "intervention": {
            "arm_group_label": "Intravitreal Lucentis 0.5mg", 
            "intervention_name": "Ranibizumab, 0.5mg, Intravitreal", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "October 20, 2013", 
        "location": {
            "contact": {
                "email": "nagaeye@kuhp.kyoto-u.ac.jp", 
                "last_name": "Nagahisa Yoshimura, MD, PhD", 
                "phone": "+81-75-751-3248"
            }, 
            "contact_backup": {
                "email": "tujikawa@kuhp.kyoto-u.ac.jp", 
                "last_name": "Akitaka Tsujikawa, MD. PhD", 
                "phone": "+81-75-751-3250"
            }, 
            "facility": {
                "address": {
                    "city": "Kyoto", 
                    "country": "Japan"
                }, 
                "name": "Department of Ophthalmology, Kyoto University Hospital"
            }, 
            "investigator": {
                "last_name": "Nagahisa Yoshimura, M.D, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "1", 
        "official_title": "Predictive Factors of 2-year Visual Outcome in Retinal Vein Occlusion Following Intravitreal Ranibizumab Treatment", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Ministry of Education, Culture, Sports, Science and Technology", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Mean foveal thickness measured by SD-OCT", 
            "safety_issue": "No", 
            "time_frame": "2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01968616"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Kyoto University, Graduate School of Medicine", 
            "investigator_full_name": "Nagahisa Yoshimura", 
            "investigator_title": "Department of Ophthalmology & Visual Sciences", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Kyoto University, Graduate School of Medicine", 
        "sponsors": {
            "collaborator": {
                "agency": "Novartis", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Kyoto University, Graduate School of Medicine", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}